… In a randomised placebo-controlled trial we treated 58 participants with type 1 diabetes
for 4–12 months with teplizumab or placebo at four academic centres in the USA. A central …

… was defined as participants with Type 1 diabetes who did not … was defined as participants
without Type 1 diabetes who … a control group with Type 1 diabetes, in which participants were …

… , we found a significant relationship between GHb and a history of depression among
participants with type 1 diabetes. This could be due in part to the data being cross-sectional. This …

… , such as type 1 diabetes (T1D). Genetic susceptibility to T1D causes alterations in the IL-2
pathway, a finding that supports Tregs as a cellular therapeutic target. Aldesleukin (Proleukin; …

… accurate prediction of type 1 diabetes is essential for appropriately identifying prevention
trial participants. Thus, we have developed a risk score for the prediction of type 1 diabetes. …

… type 1 diabetes participating in the T1D Exchange clinic registry. Data from 16,061 participants
updated between 1 September 2013 and 1 … collected from 1 September 2010 to 1 August …

Over the past decade, knowledge of the pathogenesis and natural history of type 1 diabetes
has grown substantially, particularly with regard to disease prediction and heterogeneity, …

… All participants had been diagnosed with Type 1 diabetes for at least 12 months; patients …
with Type 1 diabetes. First, over one-third of young adults with Type 1 diabetes experience …

… affect approximately 25% of people with Type 1 diabetes. While this estimate was based on
… with Type 1 diabetes were recruited by random selection over a 2-year period. Participants …

… After excluding 2955 infants for whom diabetes data were not … diabetes data, 59,130
participants remained in the analytic sample. We considered participants to have type 1 diabetes …